Arcutis Biotherapeutics
ARQT
136 hedge funds and large institutions have $684M invested in Arcutis Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 68 increasing their positions, 28 reducing their positions, and 29 closing their positions.
143% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 28
40% more call options, than puts
Call options by funds: $5.06M | Put options by funds: $3.61M
0.34% less ownership
Funds ownership: 117.18% → 116.85% (-0.34%)
5% less funds holding
Funds holding: 143 → 136 (-7)
14% less capital invested
Capital invested by funds: $797M → $684M (-$113M)
24% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 29
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$23.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$17.9M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$15.4M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.88M |
| 5 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
+$5.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$17.9M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$13.5M |
| 3 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$12.3M |
| 4 |
Barclays
London,
United Kingdom
|
-$12.2M |
| 5 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$9.85M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
E
151
Ergoteles
New York
| – | -$333K | -30,296 | Closed |
|
152
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$327K | -30,000 | Closed |
|
|
SI
153
Symmetry Investments
St Helier,
Jersey
| – | -$333K | -30,000 | Closed |
|
|
NRD
154
Nebula Research & Development
New York
| – | -$286K | -25,976 | Closed |
|
155
Two Sigma Advisers
New York
| – | -$176K | -16,000 | Closed |
|
|
PCM
156
Prelude Capital Management
New York
| – | -$161K | -14,648 | Closed |
|
|
DC
157
Diametric Capital
Boston,
Massachusetts
| – | -$161K | -14,644 | Closed |
|
158
D.E. Shaw & Co
New York
| – | -$117K | -10,629 | Closed |
|
|
GC
159
Guggenheim Capital
Chicago,
Illinois
| – | -$116K | -10,531 | Closed |
|
|
JMPWA
160
JP Morgan Private Wealth Advisors
San Francisco,
California
| – | -$111K | -10,058 | Closed |
|
|
WP
161
WealthPLAN Partners
Omaha,
Nebraska
| – | -$5.5K | -500 | Closed |
|
|
ASN
162
Advisory Services Network
Atlanta,
Georgia
| – | -$4.79K | -435 | Closed |
|
|
TWA
163
TCI Wealth Advisors
Tucson,
Arizona
| – | -$4.07K | -370 | Closed |
|
ARQT Hedge Fund Activity: Q2 2023 in Review
136 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2023, worth a combined $684M — down 14% from $797M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ARQT and 22 opened new positions — a net loss of 7 holders — while 28 trimmed existing stakes and 68 added.
The largest buyer was Jennison Associates, adding an estimated $23.1M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $17.9M sold.
- 136 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2023, down from 143 in Q1 2023.
- Funds reported $684M of Arcutis Biotherapeutics stock for Q2 2023, down 14% quarter-over-quarter.
- 22 funds opened new Arcutis Biotherapeutics positions in Q2 2023 and 29 closed out, a net change of -7 holders.
- The largest Arcutis Biotherapeutics buyer in Q2 2023 was Jennison Associates, an estimated $23.1M added.
- The largest Arcutis Biotherapeutics seller in Q2 2023 was Avidity Partners Management, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2023.